LivaNova (LIVN) Competitors $55.90 +3.04 (+5.75%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$55.90 0.00 (0.00%) As of 08/22/2025 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LIVN vs. PEN, STVN, IRTC, GKOS, BLCO, TMDX, SLNO, NVST, WRBY, and INSPShould you be buying LivaNova stock or one of its competitors? The main competitors of LivaNova include Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), Warby Parker (WRBY), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry. LivaNova vs. Its Competitors Penumbra Stevanato Group iRhythm Technologies Glaukos Bausch + Lomb TransMedics Group Soleno Therapeutics Envista Warby Parker Inspire Medical Systems LivaNova (NASDAQ:LIVN) and Penumbra (NYSE:PEN) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk. Which has more volatility & risk, LIVN or PEN? LivaNova has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500. Does the media favor LIVN or PEN? In the previous week, Penumbra had 6 more articles in the media than LivaNova. MarketBeat recorded 16 mentions for Penumbra and 10 mentions for LivaNova. LivaNova's average media sentiment score of 1.40 beat Penumbra's score of 1.24 indicating that LivaNova is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LivaNova 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 12 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer LIVN or PEN? LivaNova presently has a consensus target price of $59.71, suggesting a potential upside of 6.82%. Penumbra has a consensus target price of $300.47, suggesting a potential upside of 13.52%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than LivaNova.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 2.94 Do insiders & institutionals hold more shares of LIVN or PEN? 97.6% of LivaNova shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 0.3% of LivaNova shares are held by insiders. Comparatively, 4.2% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is LIVN or PEN more profitable? Penumbra has a net margin of 11.54% compared to LivaNova's net margin of -16.13%. LivaNova's return on equity of 14.57% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets LivaNova-16.13% 14.57% 6.91% Penumbra 11.54%11.55%8.76% Which has stronger earnings and valuation, LIVN or PEN? LivaNova has higher revenue and earnings than Penumbra. LivaNova is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLivaNova$1.25B2.44$63.23M-$3.89-14.37Penumbra$1.19B8.64$14.01M$3.7670.39 SummaryPenumbra beats LivaNova on 10 of the 17 factors compared between the two stocks. Get LivaNova News Delivered to You Automatically Sign up to receive the latest news and ratings for LIVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIVN vs. The Competition Export to ExcelMetricLivaNovaMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.05B$6.84B$5.75B$9.62BDividend YieldN/A1.31%4.40%4.10%P/E Ratio-14.3727.4531.3626.05Price / Sales2.4475.39434.71196.83Price / Cash13.1821.3437.7358.48Price / Book2.726.889.536.61Net Income$63.23M$176.42M$3.26B$265.65M7 Day Performance4.06%1.45%2.12%2.02%1 Month Performance26.70%-2.71%2.80%-0.32%1 Year Performance19.96%9.40%30.68%19.06% LivaNova Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIVNLivaNova2.4459 of 5 stars$55.90+5.8%$59.71+6.8%+21.4%$3.05B$1.25B-14.372,900News CoveragePositive NewsAnalyst ForecastPENPenumbra4.8117 of 5 stars$255.35+0.9%$300.47+17.7%+33.9%$9.87B$1.19B67.914,500Positive NewsInsider TradeSTVNStevanato Group2.1495 of 5 stars€22.50-0.5%N/A+20.9%€6.81B€1.19B41.675,521Gap DownIRTCiRhythm Technologies1.3222 of 5 stars$157.93-1.7%$157.30-0.4%+142.2%$5.16B$591.84M-53.902,000News CoverageAnalyst ForecastInsider TradeGKOSGlaukos4.7266 of 5 stars$89.47-0.4%$127.42+42.4%-27.6%$5.15B$383.48M-54.22780Analyst RevisionBLCOBausch + Lomb1.6965 of 5 stars$14.49-0.4%$15.56+7.4%-6.7%$5.15B$4.79B-18.5713,500TMDXTransMedics Group2.8397 of 5 stars$125.65-1.5%$123.00-2.1%-30.9%$4.35B$441.54M65.10210News CoveragePositive NewsSLNOSoleno Therapeutics4.5685 of 5 stars$68.09-4.9%$114.30+67.9%+41.1%$3.81BN/A-16.4530News CoverageAnalyst ForecastAnalyst RevisionNVSTEnvista3.8405 of 5 stars$20.75+0.5%$20.92+0.9%+20.6%$3.43B$2.51B64.8312,300WRBYWarby Parker2.2746 of 5 stars$27.38+0.9%$24.06-12.1%+94.9%$2.85B$771.32M-391.093,780Analyst UpgradeINSPInspire Medical Systems4.9386 of 5 stars$88.28+0.6%$165.62+87.6%-48.6%$2.60B$802.80M51.031,246News CoveragePositive NewsShort Interest ↓ Related Companies and Tools Related Companies PEN Alternatives STVN Alternatives IRTC Alternatives GKOS Alternatives BLCO Alternatives TMDX Alternatives SLNO Alternatives NVST Alternatives WRBY Alternatives INSP Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIVN) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LivaNova PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share LivaNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.